Table 1.

Patient characteristics and treatment

Arm A, vaccine + radiation therapyArm B, radiation therapy alone
No. patients1911
Age, median (range)59 (50-77)70 (56-80)
Race/ethnicity, n (%)
    White16 (84.2)8 (72.7)
    Black2 (10.5)2 (18.2)
    Hispanic2 (10.5)0 (0)
    Asian0 (0)1 (9.1)
Gleason, n (%)
    52 (10.5)0 (0)
    65 (26.3)3 (27.3)
    75 (26.3)5 (45.5)
    83 (15.8)2 (18.2)
    94 (21.1)1 (9.1)
    Median77
Stage, n (%)
    T1cN0M06 (31.6)5 (45.5)
    T2aN0M04 (21.1)0 (0)
    T2bN0M02 (10.5)1 (9.1)
    T2cNxM01 (5.3)0 (0)
    T3aN0M00 (0)1 (9.1)
    T3bN0M03 (15.8)4 (36.4)
    N13 (15.8)0 (0)
PSA at diagnosis (ng/mL), median (range)14.15 (3.84-206)8.00 (4.5-23)
Risk of biochemical failure, n (%)
    Low22
    Intermediate62
    High117
PSA on-study (ng/mL)
    Median9.864.53
    Range0.17-122.260.20-9.50
ADT
    Given15 (78.9)9 (81.8)
    Not given4 (21.1)2 (18.2)